SCHEMBL6426484

SCHEMBL6426484

O=C1C(Cl)=C(c2ccc(Cl)cc2)C(=O)N1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 3/20 0.52
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
BCHE P06276 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
ALOX12 P18054 1/20 0.47
ACHE P22303 1/20 0.47
CES1 P23141 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
RAD51 Q06609 5/20 0.44
CA12 O43570 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428843 0.89 NR1H2 (0.52) KMT2AMAPTALDH1A1TP53BCHE
SCHEMBL6428883 0.84 NR1H2 (0.48) KMT2AMAPTALDH1A1BCHECES1
SCHEMBL6427927 0.83 MAPT (0.52) KMT2ACYP1A2MAPTALDH1A1NR1H2
SCHEMBL6427000 0.82 NR1H2 (0.60) KMT2ACYP1A2CYP3A4CYP2D6MAPT
SCHEMBL6426845 0.82 MAPT (0.50) KMT2ACYP1A2CYP3A4MAPTALDH1A1
SCHEMBL6444746 0.81 RAD51 (0.50) APAF1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL28080842 0.81 APAF1 (0.57) APAF1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL6429372 0.79 SMN1; SMN2 (0.57) KMT2ACYP1A2CYP3A4CYP2D6MAPT
SCHEMBL6429547 0.79 CMA1 (0.54) KMT2AMAPTALDH1A1NR1H2NR1H3
SCHEMBL6427394 0.77 NR1H2 (0.51) BCHECES1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024755-A2 MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES DECIPHERA PHARMACEUTICALS, LLC. (US) 2005-03-17 WO disclosed